By 2030, it is anticipated that the China infectious disease therapeutics market will reach a value of $15.19 Bn from $9.64 Bn in 2022, growing at a CAGR of 5.9% during 2022-2030. Infectious Disease Therapeutics in China is dominated by a few domestic pharmaceutical companies such as WuXi Biologics, Fosun Pharma and CanSino Biologics. The infectious disease therapeutics market in China is segmented into different therapeutic areas and different treatment types. The major factors affecting the China infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various areas of China.
By 2030, it is anticipated that the China infectious disease therapeutics market will reach a value of $15.19 Bn from $9.64 Bn in 2022, growing at a CAGR of 5.9% during 2022-2030.
China is an upper middle-income developing country in East Asia bordering the East China Sea, Korea Bay, and the South China Sea. According to the World Factbook, China has a high risk of infectious diseases. Bacterial diarrhoea, hepatitis A, and typhoid fever are examples of food or waterborne infections. Crimean-Congo haemorrhagic fever and Japanese encephalitis are two vector-borne illnesses. Antibiotic resistance is an increasing worry in China, which is one of the world's major consumers of antibiotics.
China consumed an estimated 10.4 Bn daily doses of antibiotics in 2017, accounting for roughly one-third of worldwide antibiotic consumption, according to a study published in The Lancet. China's government spends 5.6 % of its GDP on healthcare in 2020.
Market Growth Drivers Analysis
China has also experienced outbreaks of new infectious diseases in recent years, such as the COVID-19 pandemic. China responded to the COVID-19 epidemic by imposing rigorous lockdown measures and increasing medicine and medical equipment production. The Chinese government has approved the use of a variety of medications for the treatment of COVID-19, including antiviral pharmaceuticals like remdesivir and traditional Chinese medicine (TCM) treatments. In China, the manufacturing business is still highly regarded, and the services sector is thriving, thanks to e-commerce trends. These characteristics could enhance China infectious diseases therapeutics market.
Market Restraints
The Chinese government has imposed pricing limitations on pharmaceutical products, particularly those used to treat infectious diseases. This can have an impact on pharmaceutical companies' profitability by limiting the prices they can charge for their products. In China, intellectual property protection is frequently regarded as lax, making it difficult for pharmaceutical companies to maintain their patents and prevent illicit manufacturing and sales of their products. In China, access to healthcare can be limited in some locations, particularly in rural areas. These factors may deter new entrants into the China infectious disease therapeutics market.
Key Players
September 2022: Shanghai Fosun Pharmaceutical, a global innovation-driven pharmaceutical and healthcare industry group with deep roots in China, announced that its subsidiary Shanghai Fosun Pharmaceutical Industry Development and Jiangsu Carephar Pharmaceutical have reached an agreement for the joint development and exclusive commercialization of Keverprazan Hydrochloride by Fosun Pharmaceutical Industrial. The scope of the agreement comprises all Keverprazan Hydrochloride oral medication products and common injectable indications. The two parties will work together on a global scale.
The National Medical Products Administration (NMPA) regulates infectious illness treatments in China. The National Medicines and Devices Agency (NMPA) is in charge of reviewing and approving new medications and medical devices, as well as monitoring their safety and efficacy. Other regulatory agencies in China, in addition to the NMPA, may be involved in the regulation of infectious illness treatments. The Chinese Center for Disease Control and Prevention (CDC), for example, is in charge of assessing the safety and efficacy of vaccinations and other biological products.
In China, the National Medical Products Administration (NMPA) and the National Healthcare Security Administration (NHSA) principally regulate the reimbursement of infectious illness treatments. The NHSA is in charge of the national health insurance system, which covers more than 95 % of the Chinese population. The NHSA assesses benefits and makes recommendations to the Ministry of Human Resources and Social Security (MOHRSS).
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
The National Medical Products Administration (NMPA) regulates infectious illness treatments in China.
In China, the National Medical Products Administration (NMPA) and the National Healthcare Security Administration (NHSA) principally regulate the reimbursement of infectious illness treatments.
Infectious Disease Therapeutics in China is dominated by domestic pharmaceutical companies such as WuXi Biologics, Fosun Pharma and CanSino Biologics.